FOLH1 and neoplasm: Both 177Lu- and 225Ac-PSMA-617 rapidly localized to the tumor, with similar uptake (14.4% ± 4.1% and 14.1% ± 4.9% injected activity/g, respectively) at 4 h after intravenous injection (not statistically significant; P = 0.89).